TEVA Teva- Pharmaceutical Industries Ltd

  1. Stocks
  2. Healthcare
  3. NYSE: TEVA

Price (delayed)

$37.34

Market cap

$43.51B

P/E Ratio

59.27

Dividend/share

N/A

EPS

$0.63

Enterprise value

$56.73B

?
Relative Growth: Rel. Growth: 35
Relative Strength: Rel. Strength: 82
Relative Valuation: Rel. Valuation: 61
Relative Profitability: Rel. Profitability: 74

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic ...

Highlights
The gross profit rose by 10% year-on-year
TEVA's gross margin is up by 6% YoY
Teva- Pharmaceutical Industries's equity has increased by 14% YoY but it has decreased by 6% QoQ
The price to earnings (P/E) is 78% higher than the last 4 quarters average of 33.3
TEVA's net income has dropped by 55% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.tevapharm.com
Peers: NVS PFE MRK AZN

Key stats

What are the main financial stats of TEVA

TEVA stock price

How has the Teva- Pharmaceutical Industries stock price performed over time
Intraday
1.44%
1 week
1.55%
1 month
19.11%
1 year
98.62%
YTD
19.64%
QTD
10.21%

Financial performance

How have Teva- Pharmaceutical Industries's revenue and profit performed over time
Revenue
$17.32B
Gross profit
$9.08B
Operating income
$1.59B
Net income
$706M
Gross margin
52.5%
Net margin
4.1%
TEVA's operating income has soared by 77% YoY but it is down by 31% from the previous quarter
The operating margin has soared by 70% YoY but it fell by 30% QoQ
TEVA's net income has dropped by 55% since the previous quarter
The net margin has dropped by 54% since the previous quarter

Price vs fundamentals

How does TEVA's price correlate with its fundamentals

Growth

What is Teva- Pharmaceutical Industries's growth rate over time

Valuation

What is Teva- Pharmaceutical Industries stock price valuation
P/E
59.27
P/B
5.61
P/S
2.51
EV/EBIT
35.13
EV/EBITDA
21.79
EV/Sales
3.28
The price to earnings (P/E) is 78% higher than the last 4 quarters average of 33.3
Teva- Pharmaceutical Industries's EPS has shrunk by 54% QoQ
TEVA's price to book (P/B) is 134% higher than its 5-year quarterly average of 2.4 and 30% higher than its last 4 quarters average of 4.3
Teva- Pharmaceutical Industries's equity has increased by 14% YoY but it has decreased by 6% QoQ
The P/S is 128% above the 5-year quarterly average of 1.1 and 32% above the last 4 quarters average of 1.9
TEVA's revenue is up by 4.1% year-on-year

Efficiency

How efficient is Teva- Pharmaceutical Industries business performance
The company's return on invested capital has surged by 95% YoY but it fell by 25% QoQ
Teva- Pharmaceutical Industries's return on sales has surged by 72% YoY but it has decreased by 30% QoQ
TEVA's ROE has plunged by 56% from the previous quarter
Teva- Pharmaceutical Industries's return on assets has shrunk by 54% QoQ

Dividends

What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Teva- Pharmaceutical Industries financials performed over time
The total assets is 24% greater than the total liabilities
Teva- Pharmaceutical Industries's current ratio has decreased by 17% YoY and by 13% QoQ
TEVA's quick ratio is down by 13% from the previous quarter and by 4.2% YoY
The debt is 118% greater than the equity
TEVA's debt to equity is down by 15% YoY but it is up by 6% from the previous quarter
Teva- Pharmaceutical Industries's equity has increased by 14% YoY but it has decreased by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.